Abstract
THE Ets-1 proto-oncogene is a member of a transcription factor family characterized by homology to the v-ets oncogene1á¤-4. In adult mice, Ets-1 is expressed predominantly in lymphoid cells where it has been implicated in regulating transcription of lymphocyte-specific genes5á¤-7. Following T-cell activation, the specific DNA binding activity of Ets-1 is inactivated by transient phosphoryla-tion, suggesting a function in the transition from the resting to activated state8,9. Ets-1 has also been suggested to cooperate with the AP-1 transcription factor complex to mediate cellular growth factor responses4. Here we show, by using RAG-2-deficient blasto-cyst complementation10, that Ets-1 deficiency has dramatic, but different, effects on development and function of T- and B-lineage cells. Ets-1-deficient T cells were present in reduced numbers and were highly susceptible to cell death in vitro. In contrast, Ets-1-deficient B cells were present in normal numbers but a large proportion were IgM plasma cells. Our data demonstrate that Ets-1 is essential for maintenance of the normal pool of resting T- and B-lineage cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Leprince, D. et al. Nature 306, 395–397 (1983).
Nunn, M. F., Seeburg, P. H., Moscovici, C. & Duesburg, P. H. Nature 306, 391–395 (1983).
Wasylyk, B. et al. Nature 346, 191–193 (1990).
Wasylyk, B., Hahn, S. L. & Giovane, A. Eur. J. Biochem. 211, 7–18 (1993).
Ho, I. C. et al. Science 250, 814–818 (1990).
Nelsen, B. et al. Science 261, 82–86 (1993).
Kola, I. et al. Proc. natn. Acad. Sci. U.S.A. 90, 7588–7592 (1993).
Rabault, B. & Ghysdael, J. J. biol. Chem. 269, 28143–28151 (1994).
Bhat, N. K. et al. Proc. natn. Acad. Sci. U.S.A. 87, 3723–3727 (1990).
Chen, J., Lansford, R., Stewart, V., Young, F. & Alt, F. W. Proc. natn. Acad. Sci. U.S.A. 90, 4528–4532 (1992).
Shinkai, Y. et al. Cell 68, 855–867 (1992).
Thomas, K. R. & Capecchi, M. R. Cell 51, 503–512 (1987).
Gunther, C. V., Nye, J. A., Bryner, R. S. & Graves, B. J. Genes Dev. 4, 667–679 (1990).
Lim, F., Kraut, N., Frampton, J. & Graf, T. EMBO J. 11, 643–652 (1992).
Boulukos, K. E., Pognovic, P., Rabault, B., Begue, A. & Ghysdael, J. Molec. cell. Biol. 9, 5718–5721 (1989).
Bottaro, A. et al. EMBO J. 13, 665–674 (1994).
Jakobovits, A. et al. Proc. natn. Acad. Sci. U.S.A. 90, 2551–2555 (1993).
Hardy, R. R., Hayakawa, K., Parks, D. R. & Herzenberg, L. A. Nature 306, 270–227 (1983).
Shultz, L. D. et al. Cell 73, 1445–1454 (1993).
Sidman, C. L., Shultz, L. D., Hardy, R. A., Hayakawa, K. & Herzenberg, L. A. Science 232, 1423–1425 (1986).
Pognonec, P., Boulukos, K. E., Gesquiere, J. C., Stehelin, D. & Gysdael, J. EMBO J. 7, 977–983 (1988).
Jorcyk, C. L., Watson, D. K., Marrothalassitis, G. J. & Papas, T. S. Oncogene 6, 523–532 (1991).
Li, E., Bestor, T. H. & Jaenisch, R. Cell 69, 915–926 (1992).
Swat, W., Ignatowicz, C. & Kisielow, P. J. immunol. Meth. 137, 79–87 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bories, JC., Willerford, D., Grévin, D. et al. Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature 377, 635–638 (1995). https://doi.org/10.1038/377635a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/377635a0
This article is cited by
-
Etv2 regulates enhancer chromatin status to initiate Shh expression in the limb bud
Nature Communications (2022)
-
Hierarchical regulation of the resting and activated T cell epigenome by major transcription factor families
Nature Immunology (2022)
-
Patients with Chromosome 11q Deletions Are Characterized by Inborn Errors of Immunity Involving both B and T Lymphocytes
Journal of Clinical Immunology (2022)
-
The antiproliferative ELF2 isoform, ELF2B, induces apoptosis in vitro and perturbs early lymphocytic development in vivo
Journal of Hematology & Oncology (2017)
-
ETS‐targeted therapy: can it substitute for MEK inhibitors?
Clinical and Translational Medicine (2017)